Evidence map›Paper›PMID 39599757›Full record

ArticleNutrients2024

HM-Chromanone Alleviates Hyperglycemia by Activating AMPK and PI3K/AKT Pathways in Mice Fed a High-Fat Diet.

Jae-Eun Park, Jeong Yoo, Ji-Sook Han

Abstract read
In one paragraph

Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jae-Eun ParkDepartment of Hotel Baking Technology, Busan Health University, Busan 49318, Republic of Korea.
Jeong YooDepartment of Food Science and Nutrition, Kimchi Research Institute, Pusan National University, Busan 46241, Republic of Korea.
Ji-Sook HanDepartment of Food Science and Nutrition, Kimchi Research Institute, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0002-6282-6815

Funding

National Research Foundation of Korea NRF-2020R1A2B5B01001547
6 · The paper itself

Abstract

objectivesWe investigated potential antihyperglycemic effects of HM-chromanone (HMC), a homoisoflavonoid isolated from

methodsFive-week-old male C57BL/6J mice (

resultsHMC supplementation significantly reduced fasting blood glucose and postprandial blood glucose levels in HFD-fed mice. HbA1c and serum insulin levels reduced significantly, and HOMA-IR improved. Compensatory β-cell hyperplasia was reduced, and pancreatic β-cell function improved. AMP-activated protein kinase (AMPK) was significantly activated in skeletal muscle and liver tissues. IRS-1tyr612 expression increased significantly. PI3K activation and Akt phosphorylation in skeletal muscles improved insulin signaling. Forkhead box protein O1 phosphorylation increased through hepatic AMPK activation. Phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression was inhibited. Glycogen synthase kinase 3β phosphorylation increased.

conclusionsHMC supplementation alleviated hyperglycemia by activating the AMPK and PI3K/Akt pathways in skeletal muscles and the AMPK pathway in the liver of HFD-fed mice.

Indexed as

AMP-Activated Protein KinasesBlood GlucoseDiet, High-FatHyperglycemiaMice, Inbred C57BLMuscle, SkeletalPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionAnimalsDietary SupplementsGlycated HemoglobinHypoglycemic AgentsInsulinInsulin ResistanceInsulin-Secreting CellsAMP-Activated Protein KinasesBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAMPKdiabetes mellitusHM-chromanonehyperglycemiainsulin resistance

Identifiers

PMID39599757
PMCPMC11597832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.